Operationalizing ADC Clinical Trials: Best Practices for Success, Upcoming Webinar Hosted by Xtalks

Join experts from Premier Research, Ashley Herrick, PhD, Vice President, Oncology Program Strategy; and Jordan Curry, Senior Project Director, Oncology, for the live webinar on Thursday, January 29, ...
GEN

Synaffix Collaborates with BigHat Biosciences on the Development of Machine Learning-Designed ADC

Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), licensed its ADC technology to BigHat Biosciences ...
ascopubs.org

Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of ...

ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will present ...
Seeking Alpha

Lonza's Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza's commitment to helping customers deliver ...